Dr Reddy's Laboratories Ltd ADR
RDY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$79.00 | Jqhyx | Kshrbdnm |
Dr. Reddy's: Well-Positioned for Future Growth Through New Products, but We Don't See a Moat
After taking a fresh look at Dr. Reddy’s, we have lowered its fair value estimate to $48 from $60 per share due to our revised future outlook of the company. Our updated forecast lies on a mid-single-digit top-line growth and an annual margin compression in its core generics portfolio as well as our updated analysis, shifting the company’s moat to no-moat from narrow.